ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q(TM) 60 BMC ("Res-Q") System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC.
In a press release issued by Celling Technologies yesterday, Dr. Mustasim Rumi of Round Rock Orthopedics said, "The Res-Q System was able to yield a high concentration of mononuclear cells, which I believe is one of the key ingredients to bone growth. This technology and Celling's service team provided me with the confidence that the cells being processed and the sterility of the procurement is the best in the industry. The market of regenerative therapies will change medicine and I believe that such cutting-edge companies give me the best opportunity to deliver the highest care to my patients," he stated.
"We are pleased with this early experience with the device as we believe the Res-Q System will help us access the growing regenerative medicine market as it has considerable advantages over competing products and has the potential to help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.
"We believe that point-of-care systems provide an immediate and efficient method for delivering adult stem cell therapy to the patients. Our research has confirmed that the Res-Q System has the features and benefits to deliver consistently high yields of mononuclear cells providing the clinician the best opportunity for successful patient outcomes. Over the next several years, we will be working closely with ThermoGenesis and our clinical partners to research and develop continued advancements in the emerging field of regenerative medicine," said Dr. Jim Poser, Executive Vice President of Regenerative Medicine of Celling Technologies.
Celling, which serves as a distributor for ThermoGenesis' MXP(TM) MarrowXpress(TM) ("MXP") System - a laboratory device also used to collect stem cells from bone marrow--also announced it is establishing the Institutes of Regenerative Medicine to further research and develop therapies for adult stems cells. As part of this initiative, ThermoGenesis and Celling Technologies will share funding of clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q Systems with Celling's orthopedic applications.
Research suggests no need for yellow fever vaccine booster after initial dose